Research & Innovation - Participant Portal

Personalising health and care

H2020-PHC-2014-two-stageSub call of: H2020-PHC-2014-2015
<
Opening Date 11-12-2013 Deadline Date 11-03-2014 17:00:00 (Brussels local time)
Publication date 11-12-2013 Total Call Budget €303,000,000
Stage 2 19-08-2014 17:00:00 (Brussels local time)
Programme Horizon 2020
Status Closed Main Pillar Societal Challenges
OJ reference OJ C 361 of 11 December 2013

Topic: Development of new diagnostic tools and technologies: in vitro devices, assays and platforms PHC-10-2014

Specific challenge: The development of new diagnostics (more sensitive, robust and selective) for improved clinical practice demands the translation of multidisciplinary scientific and technological knowledge from diverse fields into clinical applications. Innovation in this area relies on the development, translation and uptake of existing, new or evolving and often complex technologies.

Improved clinical decisions based on new and improved diagnostic tools and techniques should lead to better health outcomes while contributing to the sustainability of the health care system.

This is also a field where many small European companies are active.         

Scope: Proposals should focus on the development and application of novel in vitro diagnostic tools and technologies (including assays and platforms). The novel application of existing tools and technologies is not included. These tools and technologies should improve the performance of diagnosis, prediction, monitoring, intervention or assessment of therapeutic response, with a significant impact on clinical decisions and health outcomes.

Additionally, proposals may include approaches based on high-throughput screening, nanotechnologies or microfluidics, data analysis methodology, or technologies for point-of-care diagnostics.    

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact: This should provide:

·         Innovative, more accurate, more reliable and cost effective in vitro diagnostic tools and technologies for earlier disease diagnosis, patient stratification and/or prognosis of disease outcome leading to improved clinical decisions and health outcomes.

·         Contribution to the sustainability of health care systems.

·         Growth of the European diagnostics sector, in particular for SMEs.           

Type of action: Research and innovation actions

Please read carefully all provisions below before the preparation of your application.

  1. List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
     
  2. Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme
     
  3. Evaluation

    3.1  Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme, with the following exceptions
    The thresholds for each criterion at stage 1 (of a two stage process) will be 4 and 4. The cumulative threshold will be 8.
    The thresholds for each criterion at stage 2 (of a two stage process) will be 4, 4 and 3. The cumulative threshold will be 12.
    If a proposal fails to achieve the threshold for a criterion at any stage, the evaluation of the proposal will be stopped.
    The median of individual evaluator scores may be used at stage 1 to determine the consensus score and when appropriate, the resulting consensus report may comprise elements of these individual reports, or standard phrases representative thereof.
    The page limit for stage 1 proposals is 7 pages (including the title page).

    3.2 Guide to the submission and evaluation process
     
  4. Proposal page limits and layout: Please refer to Part B of the standard proposal template.
     
  5. Indicative timetable for evaluation and grant agreement:
    Information on the outcome of two-stage evaluation: maximum 5 months from the final date for submission.
    Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
      
  6. Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:

    Research and Innovation Action:

    Specific provisions and funding rates
    Annotated Model Grant Agreement

    pdf templates for part B of the proposal (called technical annex) and an evaluation form for this call are available under on the call page under “call documents”. If you want the Technical Annex template in word format you need to register for submission and download it from the system.
    In addition, on the same page a specific template for essential information for clinical trials/studies/investigations Applicants are requested to consult the information for clinical trials at stage one even though it has to be completed only at stage 2 and to be uploaded under call specific questions in the table of contents.
     
  7. Additional provisions:

    Horizon 2020 budget flexibility

    Classified information
     
  8. Open access must be granted to all scientific publications resulting from Horizon 2020 actions, and proposals must refer to measures envisaged. Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.

 

Additional documents

You can download the same documents as one zip file from the call page

  • Legal basis - Specific Programme H2020 en
  • WP H2020 - 1. Introduction en
  • WP H2020 - 8. Health, demographic change and wellbeing en
  • Legal basis - Framework Programme H2020 en
  • Legal basis - Rules for Participation en
  • WP H2020 - 19. General Annexes en
  • FAQ en
  • Self Evaluation form en
  • Essential information for clinical studies en
  • Part B Proposal template section 1-5 - updated 14_01_2014 en

No submission system is open for this topic.